Antidepressant use with d-Cycloserine may block fear extinction

Affiliations

Comment

Angela Fang et al. Evid Based Ment Health. 2016 Feb.

. 2016 Feb;19(1):e5.

doi: 10.1136/eb-2015-102177.

¹ Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Comment on

D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
Andersson E, Hedman E, Enander J, Radu Djurfeldt D, Ljótsson B, Cervenka S, Isung J, Svanborg C, Mataix-Cols D, Kaldo V, Andersson G, Lindefors N, Rück C. Andersson E, et al. JAMA Psychiatry. 2015 Jul;72(7):659-67. doi: 10.1001/jamapsychiatry.2015.0546. JAMA Psychiatry. 2015. PMID: 25970252 Clinical Trial.

1. Singewald N, Schmuckermair C, Whittle N, et al. . Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 2015;149:150–90. 10.1016/j.pharmthera.2014.12.004 - DOI - PMC - PubMed
1. Kushner MG, Kim SW, Donahue C, et al. . d-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007;62:835–8. 10.1016/j.biopsych.2006.12.020 - DOI - PubMed
1. Mataix-Cols D, Turner C, Monzani B, et al. . Cognitive-behavioural therapy with post-session d-Cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomized controlled trial. Br J Psychiatry 2014;204:77–8. 10.1192/bjp.bp.113.126284 - DOI - PubMed
1. Wilhelm S, Buhlmann U, Tolin DF, et al. . Augmentation of behavior therapy with d-Cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165:335–41. 10.1176/appi.ajp.2007.07050776 - DOI - PubMed
1. Smits JAJ, Rosenfield D, Otto MW, et al. . d-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biol Psychiatry 2013;73:1054–8. 10.1016/j.biopsych.2012.12.009 - DOI - PMC - PubMed